nodes	percent_of_prediction	percent_of_DWPC	metapath
Ruxolitinib—BMP2K—synovial membrane of synovial joint—ankylosing spondylitis	0.0308	0.175	CbGeAlD
Ruxolitinib—Tuberculosis—Betamethasone—ankylosing spondylitis	0.0103	0.0932	CcSEcCtD
Ruxolitinib—Tuberculosis—Dexamethasone—ankylosing spondylitis	0.0103	0.0932	CcSEcCtD
Ruxolitinib—PRKCE—tendon—ankylosing spondylitis	0.0101	0.0575	CbGeAlD
Ruxolitinib—RPS6KA6—tendon—ankylosing spondylitis	0.00971	0.0553	CbGeAlD
Ruxolitinib—Tuberculosis—Prednisone—ankylosing spondylitis	0.00898	0.0812	CcSEcCtD
Ruxolitinib—CAMK1—tendon—ankylosing spondylitis	0.00758	0.0432	CbGeAlD
Ruxolitinib—MARK2—tendon—ankylosing spondylitis	0.00736	0.0419	CbGeAlD
Ruxolitinib—TAOK2—tendon—ankylosing spondylitis	0.00681	0.0388	CbGeAlD
Ruxolitinib—JAK1—tendon—ankylosing spondylitis	0.00622	0.0354	CbGeAlD
Ruxolitinib—DCLK1—tendon—ankylosing spondylitis	0.00622	0.0354	CbGeAlD
Ruxolitinib—CAMK1D—tendon—ankylosing spondylitis	0.00607	0.0345	CbGeAlD
Ruxolitinib—PHKG2—tendon—ankylosing spondylitis	0.00603	0.0343	CbGeAlD
Ruxolitinib—DAPK2—tendon—ankylosing spondylitis	0.00593	0.0338	CbGeAlD
Ruxolitinib—STK16—tendon—ankylosing spondylitis	0.00584	0.0332	CbGeAlD
Ruxolitinib—HIPK2—tendon—ankylosing spondylitis	0.00581	0.033	CbGeAlD
Ruxolitinib—DAPK3—tendon—ankylosing spondylitis	0.00558	0.0317	CbGeAlD
Ruxolitinib—CLK2—tendon—ankylosing spondylitis	0.00553	0.0314	CbGeAlD
Ruxolitinib—BMPR2—tendon—ankylosing spondylitis	0.0052	0.0296	CbGeAlD
Ruxolitinib—CAMK2G—tendon—ankylosing spondylitis	0.00466	0.0265	CbGeAlD
Ruxolitinib—BMP2K—tendon—ankylosing spondylitis	0.00466	0.0265	CbGeAlD
Ruxolitinib—LRRK2—tendon—ankylosing spondylitis	0.00461	0.0263	CbGeAlD
Ruxolitinib—MAP3K7—tendon—ankylosing spondylitis	0.00419	0.0238	CbGeAlD
Ruxolitinib—TYK2—tendon—ankylosing spondylitis	0.00411	0.0234	CbGeAlD
Ruxolitinib—IRAK1—tendon—ankylosing spondylitis	0.00406	0.0231	CbGeAlD
Ruxolitinib—MKNK2—tendon—ankylosing spondylitis	0.00406	0.0231	CbGeAlD
Ruxolitinib—RET—tendon—ankylosing spondylitis	0.00396	0.0225	CbGeAlD
Ruxolitinib—JAK2—tendon—ankylosing spondylitis	0.00374	0.0213	CbGeAlD
Ruxolitinib—MAP3K3—tendon—ankylosing spondylitis	0.00361	0.0205	CbGeAlD
Ruxolitinib—TAOK3—tendon—ankylosing spondylitis	0.00329	0.0187	CbGeAlD
Ruxolitinib—Contusion—Dexamethasone—ankylosing spondylitis	0.00216	0.0195	CcSEcCtD
Ruxolitinib—Contusion—Betamethasone—ankylosing spondylitis	0.00216	0.0195	CcSEcCtD
Ruxolitinib—Contusion—Prednisone—ankylosing spondylitis	0.00188	0.017	CcSEcCtD
Ruxolitinib—Herpes zoster—Methotrexate—ankylosing spondylitis	0.00182	0.0165	CcSEcCtD
Ruxolitinib—Hypercholesterolaemia—Prednisone—ankylosing spondylitis	0.00173	0.0157	CcSEcCtD
Ruxolitinib—Alanine aminotransferase increased—Methylprednisolone—ankylosing spondylitis	0.00133	0.012	CcSEcCtD
Ruxolitinib—Weight increased—Prednisolone—ankylosing spondylitis	0.00129	0.0117	CcSEcCtD
Ruxolitinib—Gastrointestinal haemorrhage—Prednisone—ankylosing spondylitis	0.00119	0.0108	CcSEcCtD
Ruxolitinib—Weight increased—Triamcinolone—ankylosing spondylitis	0.00119	0.0107	CcSEcCtD
Ruxolitinib—Weight increased—Methylprednisolone—ankylosing spondylitis	0.00118	0.0107	CcSEcCtD
Ruxolitinib—Infestation—Methylprednisolone—ankylosing spondylitis	0.00116	0.0105	CcSEcCtD
Ruxolitinib—Infestation NOS—Methylprednisolone—ankylosing spondylitis	0.00116	0.0105	CcSEcCtD
Ruxolitinib—Haemoglobin—Prednisolone—ankylosing spondylitis	0.00114	0.0103	CcSEcCtD
Ruxolitinib—Haemorrhage—Prednisolone—ankylosing spondylitis	0.00113	0.0102	CcSEcCtD
Ruxolitinib—Epistaxis—Triamcinolone—ankylosing spondylitis	0.0011	0.0099	CcSEcCtD
Ruxolitinib—Weight increased—Betamethasone—ankylosing spondylitis	0.00108	0.00972	CcSEcCtD
Ruxolitinib—Weight increased—Dexamethasone—ankylosing spondylitis	0.00108	0.00972	CcSEcCtD
Ruxolitinib—Weight decreased—Dexamethasone—ankylosing spondylitis	0.00107	0.00967	CcSEcCtD
Ruxolitinib—Weight decreased—Betamethasone—ankylosing spondylitis	0.00107	0.00967	CcSEcCtD
Ruxolitinib—Alanine aminotransferase increased—Prednisone—ankylosing spondylitis	0.00105	0.00949	CcSEcCtD
Ruxolitinib—Haemoglobin—Triamcinolone—ankylosing spondylitis	0.00105	0.00947	CcSEcCtD
Ruxolitinib—Haemoglobin—Methylprednisolone—ankylosing spondylitis	0.00105	0.00945	CcSEcCtD
Ruxolitinib—Haemorrhage—Triamcinolone—ankylosing spondylitis	0.00104	0.00942	CcSEcCtD
Ruxolitinib—Haemorrhage—Methylprednisolone—ankylosing spondylitis	0.00104	0.0094	CcSEcCtD
Ruxolitinib—Neutropenia—Prednisone—ankylosing spondylitis	0.000963	0.0087	CcSEcCtD
Ruxolitinib—Haemoglobin—Dexamethasone—ankylosing spondylitis	0.000951	0.00859	CcSEcCtD
Ruxolitinib—Haemoglobin—Betamethasone—ankylosing spondylitis	0.000951	0.00859	CcSEcCtD
Ruxolitinib—Haemorrhage—Dexamethasone—ankylosing spondylitis	0.000946	0.00855	CcSEcCtD
Ruxolitinib—Haemorrhage—Betamethasone—ankylosing spondylitis	0.000946	0.00855	CcSEcCtD
Ruxolitinib—Weight increased—Prednisone—ankylosing spondylitis	0.000937	0.00847	CcSEcCtD
Ruxolitinib—Weight decreased—Prednisone—ankylosing spondylitis	0.000931	0.00842	CcSEcCtD
Ruxolitinib—Malnutrition—Methylprednisolone—ankylosing spondylitis	0.000906	0.00819	CcSEcCtD
Ruxolitinib—Haemoglobin—Prednisone—ankylosing spondylitis	0.000828	0.00748	CcSEcCtD
Ruxolitinib—Haemorrhage—Prednisone—ankylosing spondylitis	0.000824	0.00745	CcSEcCtD
Ruxolitinib—Pancytopenia—Methotrexate—ankylosing spondylitis	0.000817	0.00738	CcSEcCtD
Ruxolitinib—Neutropenia—Methotrexate—ankylosing spondylitis	0.000804	0.00727	CcSEcCtD
Ruxolitinib—Infestation—Methotrexate—ankylosing spondylitis	0.000767	0.00693	CcSEcCtD
Ruxolitinib—Infestation NOS—Methotrexate—ankylosing spondylitis	0.000767	0.00693	CcSEcCtD
Ruxolitinib—Unspecified disorder of skin and subcutaneous tissue—Methylprednisolone—ankylosing spondylitis	0.000766	0.00692	CcSEcCtD
Ruxolitinib—Infection—Triamcinolone—ankylosing spondylitis	0.000736	0.00665	CcSEcCtD
Ruxolitinib—Infection—Methylprednisolone—ankylosing spondylitis	0.000734	0.00664	CcSEcCtD
Ruxolitinib—Haematuria—Methotrexate—ankylosing spondylitis	0.000731	0.00661	CcSEcCtD
Ruxolitinib—Hepatobiliary disease—Methotrexate—ankylosing spondylitis	0.000725	0.00656	CcSEcCtD
Ruxolitinib—Nervous system disorder—Methylprednisolone—ankylosing spondylitis	0.000725	0.00655	CcSEcCtD
Ruxolitinib—Epistaxis—Methotrexate—ankylosing spondylitis	0.000724	0.00654	CcSEcCtD
Ruxolitinib—JAK3—Immune System—IL1R2—ankylosing spondylitis	0.00072	0.00101	CbGpPWpGaD
Ruxolitinib—Skin disorder—Methylprednisolone—ankylosing spondylitis	0.000718	0.00649	CcSEcCtD
Ruxolitinib—Malnutrition—Prednisone—ankylosing spondylitis	0.000717	0.00648	CcSEcCtD
Ruxolitinib—JAK1—Disease—ANTXR2—ankylosing spondylitis	0.000715	0.001	CbGpPWpGaD
Ruxolitinib—CAMK2G—Cytokine Signaling in Immune system—HLA-A—ankylosing spondylitis	0.000713	0.001	CbGpPWpGaD
Ruxolitinib—JAK3—Cytokine Signaling in Immune system—HLA-B—ankylosing spondylitis	0.000709	0.000994	CbGpPWpGaD
Ruxolitinib—IRAK1—Innate Immune System—CARD9—ankylosing spondylitis	0.000701	0.000982	CbGpPWpGaD
Ruxolitinib—MAP3K3—Cytokine Signaling in Immune system—HLA-A—ankylosing spondylitis	0.000697	0.000976	CbGpPWpGaD
Ruxolitinib—MAP3K7—MAPK Signaling Pathway—IL1A—ankylosing spondylitis	0.000695	0.000974	CbGpPWpGaD
Ruxolitinib—JAK2—MyD88:Mal cascade initiated on plasma membrane—TLR4—ankylosing spondylitis	0.000693	0.000971	CbGpPWpGaD
Ruxolitinib—MAP3K7—Adaptive Immune System—ERAP1—ankylosing spondylitis	0.000693	0.000971	CbGpPWpGaD
Ruxolitinib—Haemoglobin—Methotrexate—ankylosing spondylitis	0.000692	0.00626	CcSEcCtD
Ruxolitinib—JAK2—IL23-mediated signaling events—TNF—ankylosing spondylitis	0.00069	0.000967	CbGpPWpGaD
Ruxolitinib—IRAK1—Regulation of toll-like receptor signaling pathway—TLR4—ankylosing spondylitis	0.000689	0.000965	CbGpPWpGaD
Ruxolitinib—Haemorrhage—Methotrexate—ankylosing spondylitis	0.000689	0.00622	CcSEcCtD
Ruxolitinib—JAK3—Immune System—ERAP1—ankylosing spondylitis	0.000682	0.000956	CbGpPWpGaD
Ruxolitinib—IRAK1—Cytokine Signaling in Immune system—IL1RN—ankylosing spondylitis	0.000682	0.000955	CbGpPWpGaD
Ruxolitinib—IRAK1—Toll-Like Receptors Cascades—TLR4—ankylosing spondylitis	0.000681	0.000954	CbGpPWpGaD
Ruxolitinib—TYK2—Innate Immune System—CARD9—ankylosing spondylitis	0.00068	0.000953	CbGpPWpGaD
Ruxolitinib—CAMK2G—Immune System—CARD9—ankylosing spondylitis	0.000677	0.000949	CbGpPWpGaD
Ruxolitinib—TYK2—Interferon Signaling—HLA-B—ankylosing spondylitis	0.000675	0.000946	CbGpPWpGaD
Ruxolitinib—RET—SIDS Susceptibility Pathways—TNF—ankylosing spondylitis	0.000674	0.000945	CbGpPWpGaD
Ruxolitinib—Infection—Dexamethasone—ankylosing spondylitis	0.000668	0.00604	CcSEcCtD
Ruxolitinib—Infection—Betamethasone—ankylosing spondylitis	0.000668	0.00604	CcSEcCtD
Ruxolitinib—JAK2—MyD88-independent cascade—TLR4—ankylosing spondylitis	0.000665	0.000931	CbGpPWpGaD
Ruxolitinib—Anaemia—Prednisone—ankylosing spondylitis	0.000663	0.00599	CcSEcCtD
Ruxolitinib—TYK2—Cytokine Signaling in Immune system—IL1RN—ankylosing spondylitis	0.000662	0.000927	CbGpPWpGaD
Ruxolitinib—MAP3K3—Immune System—CARD9—ankylosing spondylitis	0.000661	0.000927	CbGpPWpGaD
Ruxolitinib—TYK2—Toll-Like Receptors Cascades—TLR4—ankylosing spondylitis	0.000661	0.000926	CbGpPWpGaD
Ruxolitinib—MAP3K7—Innate Immune System—CARD9—ankylosing spondylitis	0.00066	0.000925	CbGpPWpGaD
Ruxolitinib—Nervous system disorder—Dexamethasone—ankylosing spondylitis	0.000659	0.00596	CcSEcCtD
Ruxolitinib—Nervous system disorder—Betamethasone—ankylosing spondylitis	0.000659	0.00596	CcSEcCtD
Ruxolitinib—Thrombocytopenia—Dexamethasone—ankylosing spondylitis	0.000658	0.00595	CcSEcCtD
Ruxolitinib—Thrombocytopenia—Betamethasone—ankylosing spondylitis	0.000658	0.00595	CcSEcCtD
Ruxolitinib—JAK3—Cytokine Signaling in Immune system—HLA-A—ankylosing spondylitis	0.000657	0.000921	CbGpPWpGaD
Ruxolitinib—TYK2—DAP12 interactions—HLA-B—ankylosing spondylitis	0.00065	0.000911	CbGpPWpGaD
Ruxolitinib—MAP3K7—Regulation of toll-like receptor signaling pathway—TLR4—ankylosing spondylitis	0.000648	0.000909	CbGpPWpGaD
Ruxolitinib—PLK1—Regulation of toll-like receptor signaling pathway—TNF—ankylosing spondylitis	0.000646	0.000906	CbGpPWpGaD
Ruxolitinib—JAK1—Cytokine Signaling in Immune system—IL1A—ankylosing spondylitis	0.000645	0.000904	CbGpPWpGaD
Ruxolitinib—MAP3K7—Cardiac Hypertrophic Response—TNF—ankylosing spondylitis	0.000643	0.000901	CbGpPWpGaD
Ruxolitinib—MAP3K7—Cytokine Signaling in Immune system—IL1RN—ankylosing spondylitis	0.000642	0.000899	CbGpPWpGaD
Ruxolitinib—MAP3K7—Toll-Like Receptors Cascades—TLR4—ankylosing spondylitis	0.000641	0.000898	CbGpPWpGaD
Ruxolitinib—Fatigue—Triamcinolone—ankylosing spondylitis	0.000639	0.00577	CcSEcCtD
Ruxolitinib—Fatigue—Methylprednisolone—ankylosing spondylitis	0.000637	0.00576	CcSEcCtD
Ruxolitinib—ROCK1—MicroRNAs in cardiomyocyte hypertrophy—TNF—ankylosing spondylitis	0.000629	0.000882	CbGpPWpGaD
Ruxolitinib—TYK2—Interferon Signaling—HLA-A—ankylosing spondylitis	0.000625	0.000876	CbGpPWpGaD
Ruxolitinib—JAK3—Immune System—CARD9—ankylosing spondylitis	0.000624	0.000874	CbGpPWpGaD
Ruxolitinib—TYK2—Gastrin-CREB signalling pathway via PKC and MAPK—MMP3—ankylosing spondylitis	0.000622	0.000872	CbGpPWpGaD
Ruxolitinib—JAK1—Immune System—IL1R2—ankylosing spondylitis	0.000619	0.000868	CbGpPWpGaD
Ruxolitinib—JAK1—Cytokine Signaling in Immune system—HLA-B—ankylosing spondylitis	0.00061	0.000855	CbGpPWpGaD
Ruxolitinib—Unspecified disorder of skin and subcutaneous tissue—Prednisone—ankylosing spondylitis	0.000606	0.00548	CcSEcCtD
Ruxolitinib—Malnutrition—Methotrexate—ankylosing spondylitis	0.000599	0.00542	CcSEcCtD
Ruxolitinib—JAK2—Activated TLR4 signalling—TLR4—ankylosing spondylitis	0.000598	0.000838	CbGpPWpGaD
Ruxolitinib—JAK1—Immune System—ERAP1—ankylosing spondylitis	0.000587	0.000822	CbGpPWpGaD
Ruxolitinib—Body temperature increased—Triamcinolone—ankylosing spondylitis	0.000586	0.00529	CcSEcCtD
Ruxolitinib—Infection—Prednisone—ankylosing spondylitis	0.000582	0.00526	CcSEcCtD
Ruxolitinib—PRKCE—Disease—B3GNT2—ankylosing spondylitis	0.00058	0.000813	CbGpPWpGaD
Ruxolitinib—Gastrointestinal disorder—Dexamethasone—ankylosing spondylitis	0.00058	0.00524	CcSEcCtD
Ruxolitinib—Gastrointestinal disorder—Betamethasone—ankylosing spondylitis	0.00058	0.00524	CcSEcCtD
Ruxolitinib—Fatigue—Betamethasone—ankylosing spondylitis	0.00058	0.00524	CcSEcCtD
Ruxolitinib—Fatigue—Dexamethasone—ankylosing spondylitis	0.00058	0.00524	CcSEcCtD
Ruxolitinib—JAK1—Innate Immune System—HLA-C—ankylosing spondylitis	0.000579	0.000811	CbGpPWpGaD
Ruxolitinib—JAK2—Cytokine Signaling in Immune system—HLA-C—ankylosing spondylitis	0.000577	0.000809	CbGpPWpGaD
Ruxolitinib—Nervous system disorder—Prednisone—ankylosing spondylitis	0.000574	0.00519	CcSEcCtD
Ruxolitinib—JAK2—Immune System—KIR3DL1—ankylosing spondylitis	0.000572	0.000801	CbGpPWpGaD
Ruxolitinib—Skin disorder—Prednisone—ankylosing spondylitis	0.000569	0.00514	CcSEcCtD
Ruxolitinib—JAK1—Cytokine Signaling in Immune system—HLA-A—ankylosing spondylitis	0.000565	0.000792	CbGpPWpGaD
Ruxolitinib—JAK2—Toll Like Receptor 4 (TLR4) Cascade—TLR4—ankylosing spondylitis	0.000562	0.000788	CbGpPWpGaD
Ruxolitinib—Anaemia—Methotrexate—ankylosing spondylitis	0.000554	0.00501	CcSEcCtD
Ruxolitinib—JAK1—Immune System—CARD9—ankylosing spondylitis	0.000537	0.000752	CbGpPWpGaD
Ruxolitinib—Dizziness—Prednisolone—ankylosing spondylitis	0.000533	0.00481	CcSEcCtD
Ruxolitinib—Asthenia—Triamcinolone—ankylosing spondylitis	0.000532	0.0048	CcSEcCtD
Ruxolitinib—Body temperature increased—Dexamethasone—ankylosing spondylitis	0.000531	0.0048	CcSEcCtD
Ruxolitinib—Body temperature increased—Betamethasone—ankylosing spondylitis	0.000531	0.0048	CcSEcCtD
Ruxolitinib—Asthenia—Methylprednisolone—ankylosing spondylitis	0.00053	0.00479	CcSEcCtD
Ruxolitinib—TYK2—Disease—ANTXR2—ankylosing spondylitis	0.000528	0.00074	CbGpPWpGaD
Ruxolitinib—MAP3K2—MAPK Signaling Pathway—TNF—ankylosing spondylitis	0.000527	0.000738	CbGpPWpGaD
Ruxolitinib—Pruritus—Triamcinolone—ankylosing spondylitis	0.000524	0.00474	CcSEcCtD
Ruxolitinib—Pruritus—Methylprednisolone—ankylosing spondylitis	0.000523	0.00473	CcSEcCtD
Ruxolitinib—PRKCE—GPCR downstream signaling—PTGER4—ankylosing spondylitis	0.00052	0.000728	CbGpPWpGaD
Ruxolitinib—JAK2—Innate Immune System—CARD9—ankylosing spondylitis	0.000516	0.000723	CbGpPWpGaD
Ruxolitinib—JAK2—Interferon Signaling—HLA-B—ankylosing spondylitis	0.000511	0.000717	CbGpPWpGaD
Ruxolitinib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—ankylosing spondylitis	0.000507	0.00458	CcSEcCtD
Ruxolitinib—PRKG2—Signaling Pathways—PTGER4—ankylosing spondylitis	0.000505	0.000708	CbGpPWpGaD
Ruxolitinib—Fatigue—Prednisone—ankylosing spondylitis	0.000505	0.00456	CcSEcCtD
Ruxolitinib—Headache—Prednisolone—ankylosing spondylitis	0.000505	0.00456	CcSEcCtD
Ruxolitinib—JAK2—Cytokine Signaling in Immune system—IL1RN—ankylosing spondylitis	0.000502	0.000703	CbGpPWpGaD
Ruxolitinib—PLK1—Integrated Pancreatic Cancer Pathway—TNF—ankylosing spondylitis	0.000501	0.000702	CbGpPWpGaD
Ruxolitinib—JAK2—Toll-Like Receptors Cascades—TLR4—ankylosing spondylitis	0.000501	0.000702	CbGpPWpGaD
Ruxolitinib—JAK2—DAP12 interactions—HLA-B—ankylosing spondylitis	0.000493	0.000691	CbGpPWpGaD
Ruxolitinib—IRAK1—Cytokine Signaling in Immune system—IL1A—ankylosing spondylitis	0.000491	0.000688	CbGpPWpGaD
Ruxolitinib—Dizziness—Triamcinolone—ankylosing spondylitis	0.00049	0.00443	CcSEcCtD
Ruxolitinib—Dizziness—Methylprednisolone—ankylosing spondylitis	0.000489	0.00442	CcSEcCtD
Ruxolitinib—Infection—Methotrexate—ankylosing spondylitis	0.000486	0.00439	CcSEcCtD
Ruxolitinib—Asthenia—Dexamethasone—ankylosing spondylitis	0.000482	0.00436	CcSEcCtD
Ruxolitinib—Asthenia—Betamethasone—ankylosing spondylitis	0.000482	0.00436	CcSEcCtD
Ruxolitinib—Nervous system disorder—Methotrexate—ankylosing spondylitis	0.00048	0.00434	CcSEcCtD
Ruxolitinib—Thrombocytopenia—Methotrexate—ankylosing spondylitis	0.000479	0.00433	CcSEcCtD
Ruxolitinib—TYK2—Cytokine Signaling in Immune system—IL1A—ankylosing spondylitis	0.000476	0.000668	CbGpPWpGaD
Ruxolitinib—Pruritus—Dexamethasone—ankylosing spondylitis	0.000476	0.0043	CcSEcCtD
Ruxolitinib—Pruritus—Betamethasone—ankylosing spondylitis	0.000476	0.0043	CcSEcCtD
Ruxolitinib—Skin disorder—Methotrexate—ankylosing spondylitis	0.000475	0.00429	CcSEcCtD
Ruxolitinib—GRK1—Signaling Pathways—PTGER4—ankylosing spondylitis	0.000475	0.000665	CbGpPWpGaD
Ruxolitinib—JAK2—Interferon Signaling—HLA-A—ankylosing spondylitis	0.000474	0.000664	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling by GPCR—PTGER4—ankylosing spondylitis	0.000472	0.000661	CbGpPWpGaD
Ruxolitinib—JAK2—Gastrin-CREB signalling pathway via PKC and MAPK—MMP3—ankylosing spondylitis	0.000472	0.000661	CbGpPWpGaD
Ruxolitinib—PRKCE—Innate Immune System—HLA-B—ankylosing spondylitis	0.000471	0.000661	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—IL1R2—ankylosing spondylitis	0.000471	0.00066	CbGpPWpGaD
Ruxolitinib—PRKCE—Immune System—HLA-C—ankylosing spondylitis	0.000464	0.000651	CbGpPWpGaD
Ruxolitinib—Headache—Triamcinolone—ankylosing spondylitis	0.000464	0.00419	CcSEcCtD
Ruxolitinib—IRAK1—Cytokine Signaling in Immune system—HLA-B—ankylosing spondylitis	0.000464	0.00065	CbGpPWpGaD
Ruxolitinib—Headache—Methylprednisolone—ankylosing spondylitis	0.000463	0.00419	CcSEcCtD
Ruxolitinib—Body temperature increased—Prednisone—ankylosing spondylitis	0.000463	0.00418	CcSEcCtD
Ruxolitinib—MAP3K7—Cytokine Signaling in Immune system—IL1A—ankylosing spondylitis	0.000462	0.000647	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—IL1R2—ankylosing spondylitis	0.000457	0.00064	CbGpPWpGaD
Ruxolitinib—TYK2—Cytokine Signaling in Immune system—HLA-B—ankylosing spondylitis	0.000451	0.000631	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—ERAP1—ankylosing spondylitis	0.000446	0.000625	CbGpPWpGaD
Ruxolitinib—Dizziness—Dexamethasone—ankylosing spondylitis	0.000445	0.00402	CcSEcCtD
Ruxolitinib—Dizziness—Betamethasone—ankylosing spondylitis	0.000445	0.00402	CcSEcCtD
Ruxolitinib—MAP3K7—Immune System—IL1R2—ankylosing spondylitis	0.000443	0.000621	CbGpPWpGaD
Ruxolitinib—IRAK1—Innate Immune System—HLA-C—ankylosing spondylitis	0.00044	0.000617	CbGpPWpGaD
Ruxolitinib—JAK3—GPCR downstream signaling—PTGER4—ankylosing spondylitis	0.000439	0.000615	CbGpPWpGaD
Ruxolitinib—MAP3K7—Cytokine Signaling in Immune system—HLA-B—ankylosing spondylitis	0.000437	0.000612	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—ERAP1—ankylosing spondylitis	0.000433	0.000607	CbGpPWpGaD
Ruxolitinib—IRAK1—Cytokine Signaling in Immune system—HLA-A—ankylosing spondylitis	0.00043	0.000603	CbGpPWpGaD
Ruxolitinib—BMPR2—Signaling Pathways—PTGER4—ankylosing spondylitis	0.000429	0.000602	CbGpPWpGaD
Ruxolitinib—TYK2—Innate Immune System—HLA-C—ankylosing spondylitis	0.000427	0.000599	CbGpPWpGaD
Ruxolitinib—MAP3K7—TNF alpha Signaling Pathway—TNF—ankylosing spondylitis	0.000426	0.000597	CbGpPWpGaD
Ruxolitinib—CAMK2G—Immune System—HLA-C—ankylosing spondylitis	0.000425	0.000596	CbGpPWpGaD
Ruxolitinib—Gastrointestinal disorder—Methotrexate—ankylosing spondylitis	0.000422	0.00382	CcSEcCtD
Ruxolitinib—Fatigue—Methotrexate—ankylosing spondylitis	0.000422	0.00381	CcSEcCtD
Ruxolitinib—JAK1—Disease—B3GNT2—ankylosing spondylitis	0.000421	0.00059	CbGpPWpGaD
Ruxolitinib—Headache—Betamethasone—ankylosing spondylitis	0.000421	0.00381	CcSEcCtD
Ruxolitinib—Headache—Dexamethasone—ankylosing spondylitis	0.000421	0.00381	CcSEcCtD
Ruxolitinib—MAP3K7—Immune System—ERAP1—ankylosing spondylitis	0.00042	0.000589	CbGpPWpGaD
Ruxolitinib—Asthenia—Prednisone—ankylosing spondylitis	0.00042	0.0038	CcSEcCtD
Ruxolitinib—TYK2—Cytokine Signaling in Immune system—HLA-A—ankylosing spondylitis	0.000417	0.000585	CbGpPWpGaD
Ruxolitinib—PRKCE—Innate Immune System—CRP—ankylosing spondylitis	0.000417	0.000584	CbGpPWpGaD
Ruxolitinib—IRAK1—Toll-like Receptor Signaling Pathway—TNF—ankylosing spondylitis	0.000417	0.000584	CbGpPWpGaD
Ruxolitinib—MAP3K3—Immune System—HLA-C—ankylosing spondylitis	0.000415	0.000582	CbGpPWpGaD
Ruxolitinib—MAP3K7—Innate Immune System—HLA-C—ankylosing spondylitis	0.000414	0.000581	CbGpPWpGaD
Ruxolitinib—Pruritus—Prednisone—ankylosing spondylitis	0.000414	0.00374	CcSEcCtD
Ruxolitinib—IRAK1—Immune System—CARD9—ankylosing spondylitis	0.000408	0.000572	CbGpPWpGaD
Ruxolitinib—MAP3K7—Cytokine Signaling in Immune system—HLA-A—ankylosing spondylitis	0.000405	0.000567	CbGpPWpGaD
Ruxolitinib—PRKCE—Immune System—IL1RN—ankylosing spondylitis	0.000403	0.000565	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—ANTXR2—ankylosing spondylitis	0.0004	0.000561	CbGpPWpGaD
Ruxolitinib—GRK1—Disease—HLA-A—ankylosing spondylitis	0.0004	0.000561	CbGpPWpGaD
Ruxolitinib—PRKCE—Innate Immune System—TLR4—ankylosing spondylitis	0.000399	0.00056	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling by GPCR—PTGER4—ankylosing spondylitis	0.000398	0.000558	CbGpPWpGaD
Ruxolitinib—MAP3K7—Adaptive Immune System—HLA-C—ankylosing spondylitis	0.000398	0.000558	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—CARD9—ankylosing spondylitis	0.000396	0.000555	CbGpPWpGaD
Ruxolitinib—MAP3K7—Toll-like Receptor Signaling Pathway—TNF—ankylosing spondylitis	0.000392	0.00055	CbGpPWpGaD
Ruxolitinib—JAK3—Immune System—HLA-C—ankylosing spondylitis	0.000392	0.000549	CbGpPWpGaD
Ruxolitinib—Dizziness—Prednisone—ankylosing spondylitis	0.000387	0.0035	CcSEcCtD
Ruxolitinib—Body temperature increased—Methotrexate—ankylosing spondylitis	0.000387	0.0035	CcSEcCtD
Ruxolitinib—ROCK1—Apoptosis—TNF—ankylosing spondylitis	0.000385	0.00054	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—CARD9—ankylosing spondylitis	0.000384	0.000539	CbGpPWpGaD
Ruxolitinib—JAK1—GPCR downstream signaling—PTGER4—ankylosing spondylitis	0.000377	0.000529	CbGpPWpGaD
Ruxolitinib—RPS6KA6—Developmental Biology—TNF—ankylosing spondylitis	0.000375	0.000525	CbGpPWpGaD
Ruxolitinib—ROCK1—GPCR downstream signaling—PTGER4—ankylosing spondylitis	0.000371	0.00052	CbGpPWpGaD
Ruxolitinib—CAMK2G—Immune System—IL1RN—ankylosing spondylitis	0.000369	0.000518	CbGpPWpGaD
Ruxolitinib—Headache—Prednisone—ankylosing spondylitis	0.000367	0.00331	CcSEcCtD
Ruxolitinib—PHKG2—Disease—HLA-A—ankylosing spondylitis	0.000362	0.000507	CbGpPWpGaD
Ruxolitinib—JAK2—Cytokine Signaling in Immune system—IL1A—ankylosing spondylitis	0.000361	0.000506	CbGpPWpGaD
Ruxolitinib—MAP3K3—Immune System—IL1RN—ankylosing spondylitis	0.000361	0.000506	CbGpPWpGaD
Ruxolitinib—PRKG2—Signaling Pathways—MMP3—ankylosing spondylitis	0.00036	0.000504	CbGpPWpGaD
Ruxolitinib—PRKCE—Immune System—CD79A—ankylosing spondylitis	0.000354	0.000496	CbGpPWpGaD
Ruxolitinib—Asthenia—Methotrexate—ankylosing spondylitis	0.000351	0.00317	CcSEcCtD
Ruxolitinib—JAK2—Immune System—IL1R2—ankylosing spondylitis	0.000346	0.000485	CbGpPWpGaD
Ruxolitinib—Pruritus—Methotrexate—ankylosing spondylitis	0.000346	0.00313	CcSEcCtD
Ruxolitinib—JAK1—Signaling by GPCR—PTGER4—ankylosing spondylitis	0.000343	0.00048	CbGpPWpGaD
Ruxolitinib—JAK1—Innate Immune System—HLA-B—ankylosing spondylitis	0.000342	0.00048	CbGpPWpGaD
Ruxolitinib—JAK2—Cytokine Signaling in Immune system—HLA-B—ankylosing spondylitis	0.000341	0.000478	CbGpPWpGaD
Ruxolitinib—JAK3—Immune System—IL1RN—ankylosing spondylitis	0.00034	0.000477	CbGpPWpGaD
Ruxolitinib—GRK1—Signaling Pathways—MMP3—ankylosing spondylitis	0.000338	0.000474	CbGpPWpGaD
Ruxolitinib—JAK1—Immune System—HLA-C—ankylosing spondylitis	0.000337	0.000472	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling by GPCR—PTGER4—ankylosing spondylitis	0.000337	0.000472	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling by GPCR—MMP3—ankylosing spondylitis	0.000336	0.000471	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—ERAP1—ankylosing spondylitis	0.000328	0.00046	CbGpPWpGaD
Ruxolitinib—IRAK1—Regulation of toll-like receptor signaling pathway—TNF—ankylosing spondylitis	0.000325	0.000456	CbGpPWpGaD
Ruxolitinib—CAMK2G—Immune System—CD79A—ankylosing spondylitis	0.000324	0.000454	CbGpPWpGaD
Ruxolitinib—JAK2—Innate Immune System—HLA-C—ankylosing spondylitis	0.000324	0.000454	CbGpPWpGaD
Ruxolitinib—Dizziness—Methotrexate—ankylosing spondylitis	0.000324	0.00292	CcSEcCtD
Ruxolitinib—MAP3K3—Immune System—CD79A—ankylosing spondylitis	0.000317	0.000444	CbGpPWpGaD
Ruxolitinib—JAK2—Cytokine Signaling in Immune system—HLA-A—ankylosing spondylitis	0.000316	0.000443	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—B3GNT2—ankylosing spondylitis	0.000311	0.000436	CbGpPWpGaD
Ruxolitinib—Headache—Methotrexate—ankylosing spondylitis	0.000306	0.00277	CcSEcCtD
Ruxolitinib—MAP3K7—Regulation of toll-like receptor signaling pathway—TNF—ankylosing spondylitis	0.000306	0.000429	CbGpPWpGaD
Ruxolitinib—BMPR2—Signaling Pathways—MMP3—ankylosing spondylitis	0.000306	0.000428	CbGpPWpGaD
Ruxolitinib—MAP3K7—Adaptive Immune System—CD79A—ankylosing spondylitis	0.000303	0.000425	CbGpPWpGaD
Ruxolitinib—JAK1—Innate Immune System—CRP—ankylosing spondylitis	0.000303	0.000424	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—CARD9—ankylosing spondylitis	0.0003	0.000421	CbGpPWpGaD
Ruxolitinib—JAK3—Immune System—CD79A—ankylosing spondylitis	0.000299	0.000419	CbGpPWpGaD
Ruxolitinib—JAK1—Immune System—IL1RN—ankylosing spondylitis	0.000293	0.00041	CbGpPWpGaD
Ruxolitinib—PRKCE—Immune System—IL1A—ankylosing spondylitis	0.00029	0.000407	CbGpPWpGaD
Ruxolitinib—JAK1—Innate Immune System—TLR4—ankylosing spondylitis	0.00029	0.000406	CbGpPWpGaD
Ruxolitinib—PRKCE—Immune System—CD40LG—ankylosing spondylitis	0.000289	0.000404	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling by GPCR—MMP3—ankylosing spondylitis	0.000284	0.000397	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling Pathways—PTGER4—ankylosing spondylitis	0.000279	0.000391	CbGpPWpGaD
Ruxolitinib—PRKCE—Immune System—HLA-B—ankylosing spondylitis	0.000275	0.000385	CbGpPWpGaD
Ruxolitinib—CAMK2G—Immune System—IL1A—ankylosing spondylitis	0.000266	0.000373	CbGpPWpGaD
Ruxolitinib—CAMK2G—Immune System—CD40LG—ankylosing spondylitis	0.000264	0.00037	CbGpPWpGaD
Ruxolitinib—MAP3K7—MAPK Signaling Pathway—TNF—ankylosing spondylitis	0.000263	0.000369	CbGpPWpGaD
Ruxolitinib—IRAK1—Innate Immune System—HLA-B—ankylosing spondylitis	0.00026	0.000365	CbGpPWpGaD
Ruxolitinib—MAP3K3—Immune System—IL1A—ankylosing spondylitis	0.00026	0.000364	CbGpPWpGaD
Ruxolitinib—MAP3K3—Immune System—CD40LG—ankylosing spondylitis	0.000258	0.000362	CbGpPWpGaD
Ruxolitinib—JAK1—Immune System—CD79A—ankylosing spondylitis	0.000257	0.00036	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—HLA-C—ankylosing spondylitis	0.000256	0.000359	CbGpPWpGaD
Ruxolitinib—PRKCE—Immune System—HLA-A—ankylosing spondylitis	0.000254	0.000356	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling by GPCR—PTGER4—ankylosing spondylitis	0.000253	0.000354	CbGpPWpGaD
Ruxolitinib—TYK2—Innate Immune System—HLA-B—ankylosing spondylitis	0.000253	0.000354	CbGpPWpGaD
Ruxolitinib—CAMK2G—Immune System—HLA-B—ankylosing spondylitis	0.000251	0.000352	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—HLA-C—ankylosing spondylitis	0.000249	0.000349	CbGpPWpGaD
Ruxolitinib—MAP3K7—Adaptive Immune System—CD40LG—ankylosing spondylitis	0.000247	0.000347	CbGpPWpGaD
Ruxolitinib—MAP3K3—Immune System—HLA-B—ankylosing spondylitis	0.000246	0.000344	CbGpPWpGaD
Ruxolitinib—MAP3K7—Innate Immune System—HLA-B—ankylosing spondylitis	0.000245	0.000343	CbGpPWpGaD
Ruxolitinib—JAK3—Immune System—IL1A—ankylosing spondylitis	0.000245	0.000343	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling by GPCR—MMP3—ankylosing spondylitis	0.000244	0.000342	CbGpPWpGaD
Ruxolitinib—JAK3—Immune System—CD40LG—ankylosing spondylitis	0.000244	0.000341	CbGpPWpGaD
Ruxolitinib—PRKCE—Immune System—CRP—ankylosing spondylitis	0.000243	0.00034	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—HLA-C—ankylosing spondylitis	0.000241	0.000338	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling by GPCR—MMP3—ankylosing spondylitis	0.00024	0.000336	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—B3GNT2—ankylosing spondylitis	0.000236	0.00033	CbGpPWpGaD
Ruxolitinib—MAP3K7—Adaptive Immune System—HLA-B—ankylosing spondylitis	0.000235	0.00033	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—PTGER4—ankylosing spondylitis	0.000235	0.00033	CbGpPWpGaD
Ruxolitinib—PRKCE—Disease—HLA-A—ankylosing spondylitis	0.000235	0.000329	CbGpPWpGaD
Ruxolitinib—CAMK2G—Immune System—HLA-A—ankylosing spondylitis	0.000233	0.000327	CbGpPWpGaD
Ruxolitinib—PRKCE—Immune System—TLR4—ankylosing spondylitis	0.000233	0.000326	CbGpPWpGaD
Ruxolitinib—JAK3—Immune System—HLA-B—ankylosing spondylitis	0.000232	0.000325	CbGpPWpGaD
Ruxolitinib—IRAK1—Innate Immune System—CRP—ankylosing spondylitis	0.00023	0.000322	CbGpPWpGaD
Ruxolitinib—MAP3K3—Immune System—HLA-A—ankylosing spondylitis	0.000228	0.000319	CbGpPWpGaD
Ruxolitinib—TYK2—Innate Immune System—CRP—ankylosing spondylitis	0.000223	0.000313	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—IL1RN—ankylosing spondylitis	0.000223	0.000312	CbGpPWpGaD
Ruxolitinib—CAMK2G—Immune System—CRP—ankylosing spondylitis	0.000222	0.000311	CbGpPWpGaD
Ruxolitinib—IRAK1—Innate Immune System—TLR4—ankylosing spondylitis	0.000221	0.000309	CbGpPWpGaD
Ruxolitinib—MAP3K7—Adaptive Immune System—HLA-A—ankylosing spondylitis	0.000218	0.000306	CbGpPWpGaD
Ruxolitinib—MAP3K3—Immune System—CRP—ankylosing spondylitis	0.000217	0.000304	CbGpPWpGaD
Ruxolitinib—MAP3K7—Innate Immune System—CRP—ankylosing spondylitis	0.000217	0.000304	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—IL1RN—ankylosing spondylitis	0.000216	0.000303	CbGpPWpGaD
Ruxolitinib—JAK3—Immune System—HLA-A—ankylosing spondylitis	0.000215	0.000301	CbGpPWpGaD
Ruxolitinib—TYK2—Innate Immune System—TLR4—ankylosing spondylitis	0.000214	0.0003	CbGpPWpGaD
Ruxolitinib—CAMK2G—Immune System—TLR4—ankylosing spondylitis	0.000213	0.000299	CbGpPWpGaD
Ruxolitinib—JAK2—GPCR downstream signaling—PTGER4—ankylosing spondylitis	0.000211	0.000296	CbGpPWpGaD
Ruxolitinib—JAK1—Immune System—IL1A—ankylosing spondylitis	0.000211	0.000295	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—IL1RN—ankylosing spondylitis	0.00021	0.000294	CbGpPWpGaD
Ruxolitinib—JAK1—Immune System—CD40LG—ankylosing spondylitis	0.00021	0.000294	CbGpPWpGaD
Ruxolitinib—MAP3K3—Immune System—TLR4—ankylosing spondylitis	0.000208	0.000292	CbGpPWpGaD
Ruxolitinib—MAP3K7—Innate Immune System—TLR4—ankylosing spondylitis	0.000208	0.000291	CbGpPWpGaD
Ruxolitinib—JAK3—Immune System—CRP—ankylosing spondylitis	0.000205	0.000287	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—PTGER4—ankylosing spondylitis	0.000202	0.000284	CbGpPWpGaD
Ruxolitinib—JAK1—Immune System—HLA-B—ankylosing spondylitis	0.000199	0.000279	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—PTGER4—ankylosing spondylitis	0.000199	0.000279	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling Pathways—MMP3—ankylosing spondylitis	0.000198	0.000278	CbGpPWpGaD
Ruxolitinib—JAK3—Immune System—TLR4—ankylosing spondylitis	0.000196	0.000275	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—CD79A—ankylosing spondylitis	0.000195	0.000274	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by GPCR—PTGER4—ankylosing spondylitis	0.000192	0.000269	CbGpPWpGaD
Ruxolitinib—JAK2—Innate Immune System—HLA-B—ankylosing spondylitis	0.000191	0.000268	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—CD79A—ankylosing spondylitis	0.00019	0.000266	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—HLA-C—ankylosing spondylitis	0.000189	0.000264	CbGpPWpGaD
Ruxolitinib—JAK1—Immune System—HLA-A—ankylosing spondylitis	0.000185	0.000259	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—CD79A—ankylosing spondylitis	0.000184	0.000258	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling by GPCR—MMP3—ankylosing spondylitis	0.00018	0.000252	CbGpPWpGaD
Ruxolitinib—JAK1—Immune System—CRP—ankylosing spondylitis	0.000176	0.000247	CbGpPWpGaD
Ruxolitinib—JAK1—Disease—HLA-A—ankylosing spondylitis	0.000171	0.000239	CbGpPWpGaD
Ruxolitinib—JAK2—Innate Immune System—CRP—ankylosing spondylitis	0.000169	0.000237	CbGpPWpGaD
Ruxolitinib—JAK1—Immune System—TLR4—ankylosing spondylitis	0.000169	0.000237	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—MMP3—ankylosing spondylitis	0.000168	0.000235	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—IL1RN—ankylosing spondylitis	0.000164	0.00023	CbGpPWpGaD
Ruxolitinib—JAK2—Innate Immune System—TLR4—ankylosing spondylitis	0.000162	0.000227	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—IL1A—ankylosing spondylitis	0.00016	0.000225	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—CD40LG—ankylosing spondylitis	0.000159	0.000223	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—IL1A—ankylosing spondylitis	0.000156	0.000218	CbGpPWpGaD
Ruxolitinib—JAK1—Developmental Biology—TNF—ankylosing spondylitis	0.000155	0.000217	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—CD40LG—ankylosing spondylitis	0.000155	0.000217	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—PTGER4—ankylosing spondylitis	0.000154	0.000216	CbGpPWpGaD
Ruxolitinib—ROCK1—Developmental Biology—TNF—ankylosing spondylitis	0.000153	0.000214	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—HLA-B—ankylosing spondylitis	0.000152	0.000212	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—IL1A—ankylosing spondylitis	0.000151	0.000211	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—CD40LG—ankylosing spondylitis	0.00015	0.00021	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—PTGER4—ankylosing spondylitis	0.000149	0.000209	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—HLA-B—ankylosing spondylitis	0.000147	0.000206	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—PTGER4—ankylosing spondylitis	0.000145	0.000203	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—MMP3—ankylosing spondylitis	0.000144	0.000202	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—CD79A—ankylosing spondylitis	0.000144	0.000202	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—HLA-B—ankylosing spondylitis	0.000143	0.0002	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—MMP3—ankylosing spondylitis	0.000142	0.000199	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—HLA-A—ankylosing spondylitis	0.00014	0.000197	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by GPCR—MMP3—ankylosing spondylitis	0.000136	0.000191	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—HLA-A—ankylosing spondylitis	0.000136	0.000191	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—CRP—ankylosing spondylitis	0.000134	0.000188	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—HLA-A—ankylosing spondylitis	0.000132	0.000185	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—CRP—ankylosing spondylitis	0.00013	0.000182	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—TLR4—ankylosing spondylitis	0.000128	0.00018	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—CRP—ankylosing spondylitis	0.000126	0.000177	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—HLA-A—ankylosing spondylitis	0.000126	0.000176	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—TLR4—ankylosing spondylitis	0.000125	0.000175	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—TLR4—ankylosing spondylitis	0.000121	0.000169	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—IL1A—ankylosing spondylitis	0.000118	0.000165	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—CD40LG—ankylosing spondylitis	0.000117	0.000164	CbGpPWpGaD
Ruxolitinib—TYK2—Developmental Biology—TNF—ankylosing spondylitis	0.000114	0.00016	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—PTGER4—ankylosing spondylitis	0.000113	0.000159	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—HLA-B—ankylosing spondylitis	0.000112	0.000156	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—MMP3—ankylosing spondylitis	0.00011	0.000154	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—MMP3—ankylosing spondylitis	0.000106	0.000149	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—HLA-A—ankylosing spondylitis	0.000103	0.000145	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—MMP3—ankylosing spondylitis	0.000103	0.000145	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—CRP—ankylosing spondylitis	9.86e-05	0.000138	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—HLA-A—ankylosing spondylitis	9.54e-05	0.000134	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—TLR4—ankylosing spondylitis	9.45e-05	0.000132	CbGpPWpGaD
Ruxolitinib—JAK2—Developmental Biology—TNF—ankylosing spondylitis	8.68e-05	0.000122	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—MMP3—ankylosing spondylitis	8.06e-05	0.000113	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—B3GNT2—ankylosing spondylitis	5.58e-05	7.82e-05	CbGpPWpGaD
